Answers are grounded in this paper and cite their sources.
Experimental mouse study demonstrates delayed prion disease onset and reduced brain pathology via sortilin overexpression, suggesting lysosomal clearance as a viable therapeutic target.
Conformational conversion of the cellular isoform of prion protein, designated PrP C , into the abnormally folded, amyloidogenic isoform, PrP Sc , plays a key pathogenic role in prion diseases, including Creutzfeldt-Jacob disease in humans. We previously reported that sortilin, a member of the vacuolar protein sorting 10 protein (VPS10P) domain receptor family, could play a protective role in prion disease by functioning as a cargo receptor that delivers PrP C and PrP Sc to lysosomes for degradation. In this study, we generated transgenic mice overexpressing sortilin, termed TgSortilin mice, and intracerebrally inoculated them and control mice with various mouse-adapted prion strains. TgSortilin mice exhibited lower PrP C levels in their brains, although PrP mRNA levels were comparable between TgSortilin and control mice, suggesting that sortilin overexpression reduces PrP C levels, probably through lysosomal degradation of PrP C . Consistent with this, TgSortilin mice showed reduced susceptibility to prion infection. They eventually developed prion disease after inoculation, but with prolonged incubation times and lower brain accumulation of PrP Sc , to varying degrees depending on the inoculated prion strains. These findings indicate that sortilin overexpression lowers PrP C levels and thereby delays prion pathogenesis, suggesting that sortilin-mediated PrP C degradation may be a potential therapeutic target in prion diseases.
No takes yet. Share an insight, caveat, or question.
Batchuluun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: